|
Cortex Pharmaceuticals () is a pharmaceutical company based in Glen Rock, New Jersey specializing in positive allosteric modulators of the AMPA receptor known as Ampakines. ==History== February 2005 – Cortex received U.S. Food and Drug Administration approval to begin Phase II clinical trials for CX717 for use as a treatment for Alzheimer’s, ADHD and Sleep disorders.〔(News: Today's Orange County business briefs - OCRegister.com )〕 2006 – The FDA halted clinical trials for CX717 because they feared the drug was toxic. They later allowed testing to continue but at doses too low to have any effect.〔(Money: Innovative biomed companies woo investors - OCRegister.com )〕 July 2007 – The FDA gave Cortex permission to continue with clinical trials for CX717, as a treatment for Alzheimer's disease. September 2007 – Cortex filed with the FDA to test CX717 as a treatment for ADHD. October 2007 – Dr. Pierre Tran became Chief Medical Officer at Cortex after the FDA refused to let the company proceed with Phase II clinical trials for CX717 as a treatment for ADHD.〔(Cortex Pharmaceuticals - OC Business News - OCRegister.com )〕 March 2008 – German regulators approved clinical studies for using CX717 to prevent breathing problems caused by opiate pain-killers. May 2008 – President and CEO Dr. Roger Stoll announced that he was resigning and would be replaced by Mark Varney.〔(Cortex Pharmaceuticals - Biomedical Innovation with Colin Stewart - OCRegister.com )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cortex Pharmaceuticals」の詳細全文を読む スポンサード リンク
|